Chimeric Antibody Market Report 2025

The chimeric antibody market size has grown rapidly in recent years. It will grow from $12.27 billion in 2024 to $13.74 billion in 2025 at a compound annual growth rate (CAGR) of 12%. The growth during the historic period can be attributed to the rising incidence of cancer, increasing demand for immunotherapy, growing investment in biologics, expanded adoption of monoclonal antibodies, and the rising prevalence of autoimmune diseases.

The chimeric antibody market size is expected to see rapid growth in the next few years. It will grow to $21.31 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth during the forecast period can be attributed to an increasing focus on targeted therapies, rising clinical trial activity, expanding applications in diagnostics, a growing pipeline of biopharmaceuticals, and rising government healthcare spending. Key trends in the forecast period include the integration of technologies and ecosystems, the incorporation of genomic and precision medicine, advancements in production and engineering technologies, development of biosimilars and next-generation antibodies, and innovations in manufacturing platforms.

The rising prevalence of cancer is expected to drive growth in the chimeric antibody market in the coming years. Cancer prevalence refers to the total number of people, both newly and previously diagnosed, who are living with a history of cancer at a given time. This prevalence is increasing due to lifestyle-related risk factors, including poor diet, smoking, alcohol consumption, and exposure to environmental pollutants, which elevate the likelihood of developing various cancers. Chimeric antibodies support cancer treatment by providing targeted therapies that act specifically on tumor cells. By precisely attacking malignant cells, they reduce side effects, improve patient outcomes, and enhance treatment efficiency. For example, in July 2024, the Australian Institute of Health and Welfare reported that 160,570 cancer cases were diagnosed in Australia in 2022, up by 3,789 cases from 156,781 in 2021. Thus, the growing prevalence of cancer is fueling the expansion of the chimeric antibody market.

Key companies in the chimeric antibody market are focusing on advanced therapies, including monoclonal antibodies, to improve treatment outcomes, enhance patient survival, and address critical medical conditions. Monoclonal antibodies are laboratory-engineered proteins that replicate the immune system’s ability to combat harmful pathogens, including viruses and inflammatory agents. For instance, in June 2023, InflaRx N.V., a Germany-based biopharmaceutical firm, commercially launched Gohibic (vilobelimab), a chimeric monoclonal antibody that targets C5a in the complement system. By blocking C5a-mediated immune responses, it reduces excessive inflammation and is used to treat COVID-19 in hospitalized adults when administered within 48 hours of initiating invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). This therapy represents a major advancement in controlling hyperinflammation in severe infections, offering a novel treatment option for high-risk patients.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for approximately \$43 billion. This acquisition strengthens Pfizer’s oncology portfolio by adding Seagen’s ADC technology, approved cancer therapies, and promising late-stage candidates. Seagen Inc. is a US-based biopharmaceutical company specializing in chimeric antibody-based cancer treatments.

Major players in the chimeric antibody market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Amgen Inc., Merck KGaA, BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Lonza Group AG, Eurofins Scientific SE, Charles River Laboratories International Inc., GenScript Biotech Corporation, Biocytogen Pharmaceuticals Co. Ltd., Creative Biolabs Inc., FairJourney Biologics S.A.

North America was the largest region in the chimeric antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chimeric antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the chimeric antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Chimeric antibodies are laboratory-engineered monoclonal antibodies that combine the variable (antigen-binding) region from a non-human species, typically a mouse, with the constant region of a human antibody. This design enhances compatibility with the human immune system while preserving high target specificity.

The primary types of chimeric antibodies include immunoglobulin G (IgG) chimeric antibodies, fragment antigen-binding (Fab) chimeric antibodies, and single-chain variable fragment (ScFv) chimeric antibodies. Immunoglobulin G (IgG) chimeric antibodies are created by fusing the variable region from a non-human species with the constant region of human IgG, reducing immunogenicity while maintaining antigen specificity. They are produced using various manufacturing technologies, including recombinant DNA technology, hybridoma technology, phage display, and transgenic technology, and can be administered via intravenous (IV), subcutaneous, or intramuscular routes. These antibodies are applied in cancer therapy, autoimmune diseases, infectious diseases, and transplant rejection, serving key end users such as pharmaceutical companies, research institutes, clinics and hospitals, and diagnostic laboratories.

The chimeric antibody market research report is one of a series of new reports that provides chimeric antibody market statistics, including the chimeric antibody industry global market size, regional shares, competitors with the chimeric antibody market share, detailed chimeric antibody market segments, market trends, and opportunities, and any further data you may need to thrive in the chimeric antibody industry. This chimeric antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chimeric antibody market consists of sales of biosimilars of chimeric antibodies, diagnostic chimeric antibodies, and therapeutic chimeric antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.